Beverage and method for making a beverage for the nutritional supplementation of calcium in humans

A beverage solution is disclosed which contains per 354 ml.: 0.5-50.0 meq. of calcium ions, 0.5-50.0 meq. of magnesium ion, and 1.0-10.0 meq. of potassium ion, sweetener agent; and a stabilizer. In the beverage each of calcium, magnesium, and potassium ions is in the form of a salt such as asparatate, orotate, ascorbate, and mixtures thereof. A method of preparing or making the beverages.

FIELD OF THE INVENTION 
This invention is related to a beverage for consumption by humans. More 
specifically, this invention provides a beverage for comsumption by 
persons needing nutritional supplementation of calcium and magnesium. The 
beverage of this invention reduces blood pressure, accelerates the 
reduction of blood alcohol into inactive forms, and supplies a rapidly and 
higher absorbable source of calcium which does not cause gastric upset and 
stomach bloating. 
BACKGROUND OF THE INVENTION 
Nutrition plays an important role in all aspects of bone physiology. Poor 
eating habits will prevent normal development of bone in childhood and 
early adulthood, and can accelerate the rate of bone loss with advancing 
age. 
Although overall good nutrition is important, research has shown that the 
absolute amounts of calcium and the relative ratio of calcium to certain 
other foodstuffs in the diet are the most crucial nutrition and 
determinants of bone health. Calcium has also been discovered to lower 
blood pressure, and hypertension and has demonstrated an ability to 
suppress colon cancer. All persons experience a decline in their ability 
to absorb calcium with advancing age. Men and women also develop a 
relative deficiency in lactase, the enzyme necessary to digest the sugar 
lactose found in milk; and this leads to a decreased consumption of 
calcium-rich milk and other dairy products. In women, menopause brings on 
an additional decline in the efficiency of calcium absorption. In order to 
protect the bones of females at menopause, their calcium requirement jumps 
from a recommended daily allowance (RDA) of 800 milligrams 
(pre-menopausal) to 1400 milligrams (post-menopausal). Unfortunately, this 
is the time when many women are developing "lactose intolerance" or 
eliminating dairy products from their diet due to their contents of fats 
and sugar. North-American women on the average only consume around 450 
milligrams of calcium each day. 
Females must also be concerned with the calcium to phosphorus ratio in 
their daily diet. Phosphorus is also an essential component of bone but if 
the ratio of calcium to phosphorus falls below 2:1, then the excess 
phosphorus will compete with calcium and calcium absorption will be 
reduced. Phosphorus is widely used as a food additive and is therefore a 
major component of many processed foods, especially soft drink beverages. 
In order to maintain the proper ratio, calcium intake and absorption must 
be increased. 
Magnesium is another mineral which is essential in the daily diet. 
Magnesium combines with calcium to augment the lowering of blood pressure 
and hypertension, and further suppress colon cancer. Magnesium is also 
required for many enzyme activities and for nueromuscular transmission. 
There is some evidence that supplemental magnesium in the diet may help 
also prevent the formation of calcium oxalate stones in the kidney, and in 
females it may aid in the reduction of premenstrual tension and the 
severity of menstrual cramps. 
Potassium is also another mineral which is essential for the human body. 
Potassium has been found to additionally and further aid females in the 
reduction of premenstrual tension and severe menstrual cramps as well as 
leg cramps in active women. 
Required levels of calcium, magnesium and potassium cannot be supplemented 
by commercial, non-dairy beverages for they are unavailable. The prior art 
does not teach or suggest any beverage for nutritional supplementation of 
high levels of calcium alone, or high levels of calcium and magnesium, or 
potassium along with high levels of calcium and magnesium. 
Laborit et al in the U.S. Pat. No. 3,009,859 (patented Nov. 21, 1961) 
teaches potassium and magnesium aspartate compositions as anti-fatigue 
drugs. Laborit et al teaches that fatigue is relieved by the salts of 
aspartic acid. Laborit et al does not teach or suggest that fatigue is due 
to the replacement of essential fluids lost through perspiration and the 
physiological effects of potassium and magnesium ions. Laborit et al does 
not teach or suggest the necessity of having and administering both the 
potassium and magnesium salt of aspartic acid. Laborit et al does not 
teach or suggest the appropriate number of meq. of potassium or calcium 
ion to number of meq. of magnesium ion ratio to provide the suitable 
amount of fluid for intake by the average human body. Laborit et al does 
not teach or suggest calcium aspartate or calcium orotate for reducing 
blood pressure and reducing blood alcohol into inactive forms, and 
supplying a rapidly and higher absorbable source of calcium which does not 
cause gastric upset and stomach bloating. 
Epting Jr. in U.S. Pat. No. 4,448,770 (patented on May 15, 1984, over 
twenty-two (22) years after Laborit et al's patent) teaches prompt 
availability of electrolytes as important in maintaining body fluid 
electrolyte levels of persons, and disclose a beverage comprising an 
aqueous solution, containing per gallon: 30-50 meq. of K ion (which can be 
in the form of chloride, nitrate, sulfate, acetate, lactate, tartrate, 
benzoate, citrate, or other soluble salt, with chloride being the 
preferred); 5-10 meq. of Ca ion (which is in the form of a soluble salt 
such as acetate, chloride, gluconate, iodide, lactate, maleate, nitrate, 
and proprionate, with gluconate being the preferred); 1-3 meq. of Mg ions 
(which is introduced in the form of a soluble salt such as acetate, 
benzoate, chloride, iodide, lactate, nitrate, with chloride being the 
preferred), and sucrose which is hydrolyzed in the digestive tract to 
glucose and fructose, which are absorbed into the blood stream and further 
metabolized. Epting teachs the use of sucrose in the beverages of his 
inventions provides a carbohydrate source which permits release of energy 
in the slower but more sustained, fashion than is possible when glucose is 
used as the principal carbohydrate source. Epting discloses an aqueous 
solution containing per gallon a 1.6-10.0 Ca ion to Mg ion ratio, and a 
11.6-60K ion plus Ca ion, to Mg ion ratio. Epting Jr. does not teach or 
suggest introducing the Ca ion or the Mg ion or the K ion into the aqueous 
solution in the form of a non-soluble salt. Epting Jr's beverage could 
over medicate the average human body and limit the amount of fluid intake 
because of an insufficient quantity of Mg ions when compared to the 
quantity of K and Ca ions. The Mg ion is the "gate" ion which controls the 
absorption of the K and Ca ions from the human gut. 
Kahm in U.S. Pat. No. 4,024,684 provides a dietetic beverage containing 
sugar, sodium chloride, potassium chloride and citric acid for 
supplementing sugars and essential salts in a mammalian body, depleted 
thereof during vigorous physical exercise. 
Callaway in U.S. Pat. No. 2,224,252 discloses an alkaline food product 
containing sodium, potassium, calcium and magnesium which product is 
admixed with various food or drinks. The product is said to correct the 
acid-base balance of athletes or of people suffering from acidosis. 
Polli et al have proposed in U.S. Pat. No. 3,337,404 an effervescent 
composition, based on potassium chloride, for potassium replacement 
therapy. The composition also contains citric acid and a soluble 
sweetener. The effervescense of the composition is said to mask the 
unpalatable taste normally associated with potassium-containing solutions. 
Citrus fruit beverages of concentrates, fortified with various inorganic 
salts, have been proposed by Aktins et al (U.S. Pat. No. 3,657,424), 
Sperti, et al (U.S. Pat. No. 3,114,641) and Houghtaling et al (U.S. Pat. 
No. 3,227,562). 
A product marketed as Gatorade R contains no fruit juice, but is 
artificially flavored with lemon-lime flavoring and contains glucose, 
sucrose, citric acid, salt, sodium citrate, sodium phosphate and potassium 
citrate. The product presently available contains 16 mq of sodium and 3 mq 
of potassium per ounce. 
Hand et al in U.S. Pat. No. 4,154,814 have disclosed a therapeutic chewing 
gum containing sodium and potassium chlorides, wherein the ratio of 
NaCl:KCl is at least 3:1. 
What is needed and what has been invented by me is an all natural, 
non-dairy beverage for the nutritional supplementation in humans of 
calcium and magnesium and reducing blood pressure. What is also needed and 
what has been invented by me is a beverage which facilitates and controls 
the transport of the calcium ion into the human body, while lowering blood 
pressure and lowering the probability or tendency of incurring colon 
cancer. The beverages may also provide nutritional supplementation of 
magnesium and/or potassium to the human diet, and help to reduce 
premenstrual tension in women, and increase cardiac tolerance in 
conditions of anoxia. Any blood alcohol present in the human body is 
lowered by the beverage of this invention while supplying a rapidly and 
higher absorbable source of calcium to the human body and not causing any 
gastric upset and stomach bloating. 
SUMMARY OF THE INVENTION 
The present invention accomplishes its desired objects by broadly providing 
a method for preparing a beverage for reducing blood pressure in a human 
body while supplying a rapidly, absorbable source of calcium for the human 
body and not causing any gastric upset and stomach bloating and which is 
essentially free of sodium ion, comprising the steps of: 
(a) heating a predetermined volume of a liquid solvent to a temperature of 
at least 70.degree. F., more preferably from 180.degree. F. to 220.degree. 
F.; 
(b) adding to the heated liquid solvent of step (a), per 354 ml. of finally 
prepared beverage, 0.5-50.0 meq. of calcium ions supplied by calcium 
ascorbate and a calcium compound selected from the group consisting of 
calcium aspartate, calcium orotate, and mixtures thereof; 
(c) stirring the solution of step (b) until the calcium compound is 
dissolved in the solution; and 
(d) adding, optionally and if necessary, make-up liquid solvent to the 
solution of step (c) to obtain a final prepared beverage containing 
substantially no sodium, potassium, and magnesium ions except those 
present in minor amounts of flavoring agents, preservatives, or other 
minor additives. 
The process additionally comprise adding 0.5-50.0 meq. of magnesium ions 
supplied by a magnesium compound selected from the group consisting of 
magnesium aspartate, magnesium orotate, and mixtures thereof, and, 
optionally, magnesium ascorbate, and 1.0-10.0 meq. of potassium ions 
supplied by a potassium compound selected from the group consisting of 
potassium aspartate, potassium orotate, potassium ascorbate, and mixtures 
thereof. 
The present invention also accomplishes its desired object by broadly 
providing a beverage for reducing blood pressure in a human body while 
supplying a rapidly and higher absorbable source of calcium for the human 
body and not causing any gastric upset and stomach bloating, comprising a 
beverage solution containing per 354 ml.: 0.5-50.0 meq of calcium ion and 
1-50 g. of a sweetener. The beverage may additionally comprise 0.5-50.0 
meq of magnesium ion, and 1.0-10.0 meq. of potassium ion. The calcium ions 
are supplied by calcium ascorbate and a salt selected from the group 
consisting of aspartate, orotate and mixtures thereof. The magnesium ions 
are supplied by a salt selected from the group consisting of aspartate, 
orotate, and mixtures thereof; and, optionally, the magnesium ions may be 
additionally supplied by magnesium ascorbate. The potassium ions are 
supplied by a salt selected from the group consisting of aspartate, 
orotate, ascorbate, and mixtures thereof. The beverage additionally 
preferably comprises a tartness agent, a smoothness agent, a flavoring 
agent, and a pH adjusting agent. 
The present invention further accomplishes its desired objects by providing 
a process for reducing blood pressure in a human body and/or accelerates 
the reduction of blood alcohol in the human body into inactive forms, 
and/or supplying a rapidly and higher absorbable source of calcium for the 
human body, and not causing any gastric upset and stomach bloating 
comprising the steps of: 
(a) preparing a beverage comprising a beverage solution containing per 354 
ml.: 0.5-50.0 meq. of calcium ions supplied by calcium ascorbate and a 
calcium compound selected from the group consisting of calcium aspartate, 
calcium orotate, and mixtures thereof; and 
(b) ingesting the beverage of step (a) into a human body whose blood 
pressure is to be reduced without causing any gastric upset and stomach 
bloating. 
Therefore, it is an object of the present invention to provide beverage 
compositions which lower blood pressure and provide nutritional 
supplementation of calcium in humans while not causing gastric upset and 
stomach bloating. 
It is another object of this invention to provide beverage compositions 
which accelerate the reduction of blood alcohol into inactive forms and 
provide nutritional supplementation of potassium and magnesium in humans, 
as well as calcium, while not causing gastric upset and stomach bloating. 
It is yet another object of this invention to provide a method for making 
or preparing the beverage compositions. 
These, together with the various ancillary objects and features which will 
become apparent to those skilled in the art as the following description 
proceeds, are attained by the beverages of this invention and the method 
for preparing or making the beverages. 
DETAILED DESCRIPTION OF THE INVENTION 
The beverage compositions of this invention are for consumption by humans 
needing or desiring nutritional supplementation of calcium in their diet. 
The beverage compositions reduce blood pressure and accelerates the 
reduction of blood alcohol in the human body into inactive forms while 
supplying a rapidly and higher absorbable source of calcium for the human 
body and not causing any gastric upset and stomach bloating. The beverage 
compositions are essentially sodium free and contain no sodium ions except 
that present in minor amounts of flavoring agents, preservatives, or other 
additives. 
In a preferred embodiment of the invention, the beverage compositions 
comprise a beverage solution containing per 354 ml.: 0.5-50.0 meq. of 
calcium ions supplied by calcium ascorbate and a calcium compound selected 
from the group consisting of calcium aspartate, calcium orotate, and 
mixtures thereof; and 1.0-50.0 g. of a sweetener agent. More preferably, 
the beverage composition comprises a beverage solution containing per 354 
ml.: 0.5-10.0 meq. of calcium ions supplied by calcium ascorbate and a 
calcium compound selected from the group consisting of calcium aspartate, 
calcium orotate, and mixtures thereof; and 10.0-40.0 g. of a sweetener 
agent. Most preferably the calcium compound is calcium aspartate. The 
preferred embodiment of the beverage compositions preferably additionally 
comprise per 354 ml. of beverage solution; from about 0.02 g. to about 
3.50 g. of a tartness agent; from about 0.25 g. to about 1.0 g. of a pH 
adjusting agent in order to adjust the pH of the preferred embodiment of 
the beverage from about 3.0 to about 4.5; from about 0.10 g. to about 3.0 
g. of a smoothness agent; and from about 0.05 ml. to about 50.0 ml. of a 
flavoring agent. This preferred embodiment of the beverage compositions 
are to be consumed by persons who wish to supplement dietary calcium, 
lower their blood pressure, accelerate the reduction of blood alcohol into 
inactive forms, and lower any probability or tendency of incurring colon 
cancer. 
In a more preferred embodiment of the present invention, the beverage 
compositions comprise a beverage solution containing per 354 ml.: 0.5-50.0 
meq. of calcium ions supplied by calcium ascorbate and a calcium compound 
selected from the group consisting of calcium aspartate, calcium orotate, 
and mixtures thereof; 0.5-50.0 meq. of magnesium ions supplied by a 
magnesium compound selected from the group consisting of magnesium 
aspartate, magnesium orotate, and mixtures thereof; and 1.0-50.0 g of a 
sweetener agent. In addition to the magnesium ions being supplied from 
magnesium aspartate and/or magnesium orotate, the magnesium ions may be 
supplied by magnesium ascorbate. A purpose for employing and furnishing 
the magnesium ions in the stated meq. is to facilitate and control the 
transport of the calcium ions into the average human body for use while 
simultaneously providing nutritional supplementation of magnesium to the 
human diet. Supplementing the calcium compound(s) with the magnesium 
compound(s) also provides a greater effect in lowering blood pressure, 
accelerating the reduction of blood alcohol into inactive form, and 
decreasing any probability or tendency of incurring colon cancer in the 
average human being than if the calcium compound was employed alone. More 
preferably, the beverage compositions in this more preferred embodiment of 
the present invention comprises a beverage solution containing per 354 ml: 
0.5-10.0 meq. of calcium ions supplied by calcium ascorbate and a calcium 
compound selected from the group consisting of calcium aspartate, calcium 
orotate, and mixtures thereof; 0.5-5.0 meq. of magnesium ions supplied by 
a magnesium compound selected from the group consisting of magnesium 
aspartate, magnesium orotate, and mixtures thereof; and 10.0-40.0 g. of 
the sweetener agent. The magnesium ions may also be supplied by magnesium 
ascorbate in addition to being supplied by magnesium aspartate and/or 
magnesium orotate. This more preferred embodiment of the beverage 
compositions preferably additionally comprise per 354 ml. of beverage 
solution: from about 0.20 g. to about 1.5 g. of a tartness agent; from 
about 0.30 g. to about 0.90 g. of a pH adjusting agent in order to adjust 
the pH of the more preferred beverage from about 3.0 to about 4.5; from 
about 0.15 g. to about 2.0 g. of a smoothness agent; and from about 0.10 
ml. to about 45.0 ml. of a flavoring agent. In this more preferred 
embodiment for the beverage compositions, the beverage is essentially free 
of potassium ions in that the beverage composition contains no potassium 
ions except that present in minor amounts of flavoring agents, 
preservatives, or other minor additives. 
For those persons needing additional potassium in their diet, such as women 
in reducing premenstrual tension, the calcium and magnesium compounds of 
this invention may be combined with a potassium compound to produce a most 
preferred embodiment of the present invention wherein the beverage 
compositions comprise a beverage solution containing per 354 ml.: 0.5-50.0 
meq. of calcium ions supplied by calcium ascorbate and a calcium compound 
selected from the group consisting of calcium aspartate, calcium orotate, 
and mixtures thereof; 0.5-50.0 meq. of magnesium ions supplied by a 
magnesium compound selected from the group consisting of magnesium 
aspartate, magnesium orotate and mixtures thereof, and, optionally, the 
magnesium ions may be additionally supplied by magnesium ascorbate; 
1.0-10.0 meq. of potassium ions supplied by a potassium compound selected 
from the group consisting of potassium aspartate, potassium orotate, 
potassium ascorbate, and mixtures thereof; and 1.0-50.0 g. of a sweetener 
agent. In addition to providing the magnesium ions to facilitate and 
control the transport of the calcium ions into the average human body, the 
stated meq. of the magnesium ions facilitates and controls the transport 
of the potassium ions into the average human body for use, while also 
simultaneously providing nutritional supplementation of magnesium to the 
human diet. Furthermore, the stated meq. of the magnesium ions and the 
stated meq. of the calcium ions, given in conjunction with the stated meq. 
of the potassium ions, in conditions of anoxia generally increases the 
cardiac tolerance of the condition, while the potassium ions alone, is 
generally ineffective. More preferably with respect to this most preferred 
embodiment of the present invention, the beverage compositions comprise a 
beverage solution containing per about 354 ml.: 0.5-10.0 meq. of calcium 
ions supplied by calcium ascorbate and a calcium compound selected from 
the group consisting of calcium aspartate, calcium orotate, and mixtures 
thereof; 0.5-5.0 meq. of a magnesium ions supplied by a magnesium compound 
selected from the group consisting of magnesium aspartate, magnesium 
orotate, and mixtures thereof, and, optionally, the supply of magnesium 
ions may additionally come from magnesium ascorbate; 1.0-2.0 meq. of 
potassium ions supplied by a potassium compound selected from the group 
consisting of potassium aspartate, potassium orotate, potassium ascorbate 
and mixtures thereof; and 10.0-40.0 g. of a sweetener agent. Most 
preferably, the calcium compound is calcium aspartate, the magnesium 
compound is magnesium aspartate, and the potassium compound is potassium 
aspartate. In this most preferred embodiment of the invention, the 
beverage preferably additionally comprises a beverage solution containing 
per 354 ml.: from about 0.3 g. to about 0.7 g. of a tartness agent; from 
about 0.30 g. to about 0.60 g. of a pH adjusting agent in order to adjust 
the pH of the most preferred embodiment of the beverage from about 3.0 to 
about 4.5; from about 0.20 g. to about 0.6 g. of a smoothness agent; and 
from about 0.18 ml. to about 36 ml. of a flavoring agent. 
The beverage compositions of this invention may be consumed by persons 
desiring nutritional supplementation calcium in the daily human diet. If 
magnesium supplementation, or magnesium and potassium supplementation, is 
needed, such supplementation may be added in accordance with the stated 
meq. The beverage compositions are all-natural, non-dairy compositions 
which may be consumed periodically in place of water or other beverages. 
The beverages are prepared to be highly palatable, and do not irritate the 
gastric mucosa. The calcium ion alone embodiment of the invention, or the 
calcium ion plus magnesium ion alone embodiment, reduces or lowers blood 
pressure in a human being blood and/or supplies a rapidly and higher 
absorbable source of calcium to a human body (or animal), all while not 
causing any gastric upset and stomach bloating. 
The beverage compositions are rapidly absorbed into the blood stream, and 
do not contain high amounts of sodium, glucose, dextrose, sucrose or 
synthetic sweeteners, artificial coloring or flavoring, preservatives, or 
other non-essential elements which may cause nausea and/or inhibit the 
absorption of fluids by the average human body. 
An important active constituent(s) in the beverage compositions of this 
invention are the chelating agent(s). I have discovered that the active 
chelates chosen should preferably be of natural origin, non-toxic, 
non-irritating to the buccal cavity, alimentary canal, gastric mucosa, or 
the intestinal tract. The chelates should preferably also be tightly 
bound, easily absorbed and transferred to the muscle cells, easily 
metabolised, and must not interfere with the absorpiton of water by the 
intestines. 
In a preferred embodiment of this invention, the chelates of the beverage 
compositions of this invention are the chelates of ascorbate, aspartate 
and orotate chelates; more specifically, as was previously mentioned, 
calcium ascorbate Ca(C.sub.8 H.sub.7 O.sub.6).sub.2, calcium aspartate 
(C.sub.8 H.sub.12 Ca N.sub.2 O.sub.8), calcium orotate [(C.sub.5 H.sub.3 
N.sub.2 O.sub.4).sub.2 Ca. 2.5 H.sub.2 O], potassium ascorbate (K C.sub.6 
H.sub.7 O.sub.6), potassium asparate (C.sub.4 H.sub.6 KNO.sub.4), 
potassium orotate (C.sub.5 H.sub.3 N.sub.2 O.sub.4.K. 2.5 H.sub.2 O), 
magnesium ascorbate Mg (C.sub.6 H.sub.7 O.sub.6)2, magnesium aspartate 
(C.sub.8 H.sub.12 M.sub.g N.sub.2 O.sub.8), and magnesium orotate 
[(C.sub.5 H.sub.3 N.sub.2 O.sub.4).sub.2 Mg. 2.5 H.sub.2 O]. These 
particular chelates are non-toxic, tightly bound, non-irritating to the 
buccal cavity, alimentary canal, gastric muscosa or intestinal tract. 
These particular chelates also do not impede the absorption of water from 
the intestinal tract because of the fact that their ionic charge is 
opposite to that of the gastric mucosa or intestinal wall. They are easily 
absorbed and are quickly transferred to the tissues whereupon any released 
calcuim ions, magnesium ions, and potassium ions, enter the cells to 
replace calcium, magnesium and potassium, respectively, which may have 
been depleted. The amino acid is then metabolised. These chelate 
substances are physiologically compatible with the systems of humans. 
When the beverages of this invention are administered and ingested to a 
human body, the calcium ascorbate and/or calcium aspartate and/or calcium 
orotate contained within the beverage provides a rapid and highly 
absorbable source of calcium to the human body. I have discovered that the 
aspartate and orotate salts of calcium are not readily soluble salts. The 
aspartate, orotate, and ascorbate salts of calcium allow the calcium ion 
to be absorbed in the human body quicker than other calcium salts, such as 
when the calcium ion is in the form of chloride, nitrate, acetate, 
lactate, gluconate, iodide, maleate, propionate, which are soluble salts. 
As used in this specification and the appended claims, the beverage 
solution for the purposes of this invention contains not only the beverage 
ingredients but also comprises from about 70 vol % to about 90 vol. % of a 
"liquid solvent", which is compatible for the purposes of this invention 
and is generally th starting material in preparing and making the 
beverages. 
Stated alternatively, each 354 ml of the beverage solution would contain 
from about 247.8 ml. to about 318.6 ml. of the "liquid solvent" as the 
major component of the beverage solution. While not intending to be bound 
by any particular liquid, the "liquid solvent" would include pure liquids, 
and liquid solutions, both alcoholic and non-alcoholic, and may more 
particularly include, but not be limited to, aqueous solutions, carbonated 
water, non-carbonated water, mineral water, distilled water, soft drinks, 
beer, malt and/or hop beverages, wine, coffee, tea, alcoholic mixed drinks 
in general, as long as such pure liquids and liquid solutions meet the 
specifications of the present invention. Preferably, the liquid solvent is 
demineralized, carbon filtered potable water. Carbonation is added to a 
level of 3.6-3.9 parts. 
It is to be understood that while the preferred calcium chelates for 
supplying or forming 0.5-50 meq. of calcium ions are calcium ascorbate, 
and calcium aspartate and/or calcium orotate, the 0.5-50 meq. of calcium 
ions may be supplied solely by calcium aspartate and/or calcium orotate. 
The ascorbate salt of calcium employed along with the calcium aspartate 
and/or the calcium orotate performs the following dual purpose: (1) the 
ascorbate anion of calcium ascorbate along with calcium aspartate and/or 
calcium orotate, aids the absorption of the calcium ion into the blood 
stream of the human body (2) the ascorbate anion of calcium ascorbate, as 
opposed to calcium aspartate and/or calcium orotate, also aids the use by 
the human body of the calcium ions (that have been absorbed into the 
blood) for formation of bone matrix by directing, causing and/or 
facilitating the cause of the calcium ions to migrate or travel, or the 
like, to the bones of the human body to form the bone matrix. Stated 
Alternatively, the ascorbate anion from calcium ascorbate directs or 
channels the calcium ions towards the bones of the human body for use in 
the formation of bone matrix before other parts including tissues of the 
human body have absorbed a substantial portion of the calcium ions. 
Obviously, even with the employment of calcium ascorbate, some of the 
other parts and tissues of the human body will absorb some of the calcium 
ions. Similarly, without the employment of calcium ascorbate, obviously 
some bone matrix will be formed from the calcium ions that have been 
absorbed into the blood from the calcium aspartate and/or calcium orotate. 
But ascorbate anion from calcium ascorbate provides a catalyst to 
expedite, speed-up or bias the movement or travel of the calcium ions from 
the blood stream to the bones of the human body, when calcium ascorbate is 
employed with calcium aspartate and/or calcium orotate. 
I have also discovered that by employing calcium aspartate and/or calcium 
orotate with calcium ascorbate in a ratio of from approximately 1.2 to 
about 2.8 parts of the calcium aspartate and/or calcium orotate to about 1 
part calcium ascorbate (with the preferred ratio being about 1.5) that the 
combination enables a greater portion or amount of the calcium ions 
supplied from both calcium compounds to be absorbed into the blood stream 
of a human body than if the calcium ascorbate, or the calcium aspartate 
and/or calcium orotate were employed alone. For example, if a beverage 
solution containing per 354 ml. 25 meq. or calcium ions supplied by 1.5 
parts of calcium aspartate and/or calcium orotate to 1 part calcium 
ascorbate, is administered to a set of human subjects and the amount of 
calcium ions in the blood is determined every half hour from blood samples 
taken from human subjects every half hour, it would be found that on an 
average a larger portion of the 25 meq. of calcium ions would have been 
absorbed into the blood stream than if a beverage solution containing per 
354 ml. 25 meq. of calcium ions supplied solely by calcium ascorbate, or 
solely by calcium aspartate and/or calcium orotate, is administered to a 
similar set of human beings with the amount of calcium ions in the blood 
being measured at the same half hour time intervals. Thus, the ascorbate 
anion from calcium ascorbate provides a synergistic effect with respect to 
the amount of meq. of calcium ions that are absorbed into the blood when 
calcium ascorbate is combined with calcium asparate and/or calcium 
orotate. 
I have further discovered that by using calcium ascorbate with calcium 
aspartate and/or calcium orotate in the beverage compositions of this 
invention, the bone mass after a predetermined period of time of consuming 
the beverage compositions will be from about 10% to about 35% by weight 
greater than if the calcium aspartate and/or calcium orotate were used 
alone without a certain quantity of the calcium ions emanating from 
calcium ascorbate. When 0.5-50 meq. of calcium ions are to be supplied by 
calcium ascorbate and calcium aspartate and/or calcium orotate, in order 
to receive the benefit of having 10-35% by weight greater bone mass from 
consumption after a predetermined period of time, at least 15% of the 
0.5-50 meq. of calcium ions should be supplied by calcium ascorbate. More 
preferably, 40-60% of the 0.5-50 meq. of calcium ions should be supplied 
by calcium ascorbate. In a preferred embodiment of the invention, I have 
discovered that if less than about 15% of the 0.5-50 meq. of calcium ions 
are supplied in the beverage compositions by calcium ascorbate, there 
would be less than about 10% by weight increase in bone mass when compared 
to employing only calcium aspartate and/or calcium orotate in the beverage 
compositions. Thus, there is no substantial benefit from the calcium 
ascorbate with respect to increasing bone mass unless at least about 15% 
of the 0.5-50 meq. of calcium ions are supplied by calcium ascorbate. In 
order to generally provide or supply at least 15% of the 0.5-50 meq. of 
calcium ions from calcium ascorbate, per each 354 ml. beverage solution 
preferably contains from about 10 mg. to about 150 mg. of calcium 
ascorbate. More preferably, 30 mg. to 90 mg. of calcium ascorbate is 
contained within each 354 ml. of beverage solution. Most preferably, each 
354 ml. of beverage solution contains about 60 mg. of calcium ascorbate, 
the required daily allowance (RDA). 
It is to be also understood that while the preferred magnesium chelates for 
supplying or forming 0.5-50 meq. of magnesium ions are magnesium asparate 
and/or magnesium orotate, in the event or situation where no or not enough 
calcium ascorbate is available to supply the preferred amount (i.e. 10 mg 
to 150 mg.) of calcium ascorbate per 354 ml. of beverage solution, then 
the preferred amount or remaining amount of ascorbate anions may be 
supplied by magnesium ascorbate. Generally, if no calcium ascorbate is 
available, each 354 ml. of beverage solution contains from about 5 mg. to 
about 120 mg. of magnesium ascorbate. If not enough ascorbate anions has 
been added from calcium ascorbate, the remaining ascorbate anions may be 
supplied from magnesium ascorbate in an amount readily discernible to 
those artisans possessing ordinary skill in the art. By way of example 
only, if only 30 mg. of calcium ascorbate has been added to each 354 ml. 
of beverage solution, the remaining ascorbate anions to reach the 
equivalent ascorbate in 60 mg. of calcium ascorbate may be supplied by the 
addition of about 18 mg. of magnesium ascorbate. If all or a portion of 
the required ascorbate anions is supplied by magnesium ascorbate, then the 
previously mentioned synergistic and unexpected results that were seen for 
calcium ascorbate would likewise apply to magnesium ascorbate. More 
specifically, the ascorbate anions from magnesium ascorbate, along with 
calcium aspartate and/or calcium orotate, aids the absorption of the 
calcium ion into the blood stream of the human body, and the ascorbate 
anion from magnesium ascorbate, as opposed to calcium aspartate and/or 
calcium orotate, also aids the use by the human body of the calcium ions 
for formation of bone matrix by directing, causing and/or facilitating the 
cause of the calcium ions to migrate or travel to the bones of the body to 
form the bone matrix. The ascorbate anion from magnesium is also a 
catalyst for speeding-up the travel of the calcium ions from the blood 
stream to the bones of the human body. If the comparable amount of the 
ascorbate anion in calcium ascorbate is furnished all or in part by 
magnesium ascorbate, and a ratio comparable to the 1.2-2.8 ratio of 
calcium aspartate and/or calcium orotate to calcium ascorbate is employed 
for the magnesium ascorbate (i.e. about 1.6 to about 4.0 parts of the 
calcium aspartate and/or calcium orotate to about 1 part magnesium 
ascorbate) that combination enables a greater portion or amount of the 
calcium ions supplied by calcium aspartate and/or calcium orotate to be 
absorbed into the blood stream of the human body than if calcium asparate 
and/or orotate wa employed alone. By combining magnesium ascorbate and 
calcium ascorbate together to make-up the required amount of ascorbate, 
the ratio of the calcium aspartate and/or calcium orotate to the 
combination of ascorbate compounds would preferably be from about 1.2 to 
about 4.0. Similarly, if all or a portion of the requried ascorbate anions 
are supplied by magnesium ascorbate, the bone mass after a predetermined 
period of time of consuming the beverage compositions will also be from 
about 10% to about 35% by weight greater than if the calcium aspartate 
and/or calcium orotate were used alone without the magnesium ascorbate or 
the combination of magnesium ascorbate plus calcium ascorbate. 
The beverage compositions of this invention also include a sweetener agent. 
Preferably, the sweetener agent is selected from the group consisting of 
fructose, aspartame, stevioside, stevia, raubidicide A, and mixtures 
thereof. More preferably, the sweetener agent is selected from the group 
consisting of fructose, stevioside, Raubidiscide A, and mixtures thereof. 
Most preferably, the sweetneer agent is fructose. 
Fructose is clearly the preferred sweetener agent for this invention in the 
non-dietetic form. Other sweeteners such as sucrose and glucose are not 
preferred. Sucrose is hydrolyzed in the digestive tract of the average 
human body into glucose and fructose. By employing pure fructose, in the 
beverage compositions of this invention, fructose becomes immediately 
available for absorption by the human body instead of having to wait for 
its availability as a by-product of a would-be sweetener such as sucrose. 
Fructose is the sweetest of all sugars and does not cause a marked rise in 
blood sugar as glucose does. This is important because high blood sugar 
levels also cause the production of insulin which will subsequently cause 
blood sugar levels to fall off rapidly to low or below normal levels. Such 
rapid decline in blood sugar levels results in immediate fatigue to the 
average human body. Fructose is prepared commercially in the crystalline 
form and even though it is presently one of the more expensive sugars, 
less fructose is to be used which makes it cost effective for the purposes 
of this invention. 
The tartness agent is preferably incorporated in the beverage compositions 
of this invention in order to control tartness. The agent used for 
tartness is preferably natural and acidic. A preferred tartness agent is 
citric acid, and each 354 ml. of the beverage solution comprises from 
about 0.05 g. to about 0.7 g. of the citric acid. 
Th pH adjusting agent, or preservative, is also preferably incorporated 
into the beverage compositions of this invention in order to adjust the pH 
of the beverage from about 3.0 to about 4.5 to preserve the beverage. The 
pH adjusting agent used as a preservative is preferably natural and 
bacteriostatic. A preferred pH adjusting agent is benzoic acid (C.sub.7 
H.sub.6 O.sub.2), and from about 0.35 g. to about 0.65 g. of the benzoic 
acid per each 354 ml. of the beverage solution, is added to the aqueous 
solution to adjust the pH of the beverage from about 3.0 to about 4.5. 
A flavoring agent is recommended for the beverage compositions of this 
invention in order to mask any unpalatable taste that may originate from 
any of the beverage components. The flavoring agent is preferably all 
natural, non-toxic and pleasing to wide ranges of the population. Suitable 
flavoring agents have been found to be the lemon flavor #109715 FD&O 
(Fritche, Dodge and Olcott) and/or fruit punch flavor by FD&O. Preferred 
flavoring agents are natural fruit juices (e.g. orange juice, pineapple 
juice, apple juice, etc.) or extracts therefrom. The flavoring that each 
354 ml. of beverage solution has is from about 0.18 ml. to about 36.0 ml. 
of the flavoring agent(s). 
Another recommended agent for the beverage compositions of this invention 
is a smoothness agent for controlling the smoothness of the beverage. The 
agent for smoothness is preferably natural, and is a salt of the agent 
used for tartness. A preferred smoothness agent is selected from potassium 
citrate, calcium citrate, and mixtures thereof, which is a salt of a 
preferred tartness agent, citric acid. The potassium or calcium citrate, 
or a mixture of potassium and calcium citrate, is included in the beverage 
compositions of this invention comprises, per 354 ml. of beverage of 
solution, from about 0.20 g. to about 0.60 g. of potassium citrate or 
calcium citrate, or a mixture of potassium and calcium citrate. 
The beverage compositions may be dehydrated to be in a form of a dry 
mixture suitable for reconstituting with a liquid solvent into the 
beverage compositions. In a preferred embodiment of the dry mixture, the 
dry beverage mixture comprises 0.5-50.0 meq. of calcium ions supplied by 
calcium ascorbate and a calcium compound selected from the group 
consisting of calcium aspartate, calcium orotate, and mixtures thereof, 
per 1.0-50.0.0 g. of the sweetener agent. Preferably, in this preferred 
embodiment of the dry mixture, the dry beverage mixtures comprises 
0.5-10.0 meq. of calcium ions supplied by calcium ascorbate and a calcium 
compound selected from the group consisting of calcium aspartate, calcium 
orotate, and mixtures thereof, per 1.0-50.0 g. of the sweetener agent. The 
preferred embodiment of the dry mixture compositions preferably 
additionally comprise per 1.0-50.0 g. of the sweetener agent: from about 
0.02 g. to about 3.5 g. of the tartness agent; from about 0.25 g. to about 
1.0 g. of the pH adjusting agent; from about 0.1 g. to about 3.0 g. of the 
smoothness agent; and from about 0.05 ml. to about 50.0 ml. of the 
flavoring agent. 
In a more preferred embodiment of the dry mixture, the dry mixture 
comprises 0.5-50.0 meq. of calcium ions supplied by calcium ascorbate and 
a calcium compound selected from the group consisting of calcium 
aspartate, calcium orotate, and mixtures thereof, per 1.0-50.0 g. of the 
sweetener agent; and 0.5-50.0 meq. of magnesium ions supplied by a 
magnesium compound selected from the group consisting of magnesium 
aspartate, magnesium orotate, and mixtures thereof, per 1.0-50.0 g. of the 
sweetener agent. In addition to the magnesium ions being supplied from 
magnesium aspartate and/or magnesium orotate, the magnesium ions may be 
supplied by magnesium ascorbate. Preferably, in this more preferred 
embodiment of the dry mixture, the dry beverage mixture comprises 0.5-10.0 
meq. of calcium ions supplied by calcium ascorbate and a calcium compound 
selected from the group consisting of calcium aspartate, calcium orotate, 
and mixtures thereof, per 10.0-40.0 g. of the sweetener agent; and 0.5-5.0 
meq. of magnesium ions supplied by a magnesium compound selected from the 
group consisting of magnesium aspartate, magnesium orotate, and mixtures 
thereof, per 10.0-40.0 g. of the sweetener agent. The magnesium ions may 
be additionally supplied from magnesium ascorbate. The more preferred 
embodiment of the dry mixture compositions preferably additionally 
comprise per 1.0-50.0 g. of the sweetener agent: from about 0.2 g. to 
about 1.5 g. of the tartness agent; from about 0.30 g. to about 0.9 g. of 
the pH adjusting agent; from about 0.15 g. to about 2.0 g. of the 
smoothness agent; and from about 0.1 ml. to about 45.0 ml. of the 
flavoring agent. As was the case for the more preferred embodiment of the 
beverage compositions, the more preferred embodiment of the dry beverage 
mixture is essentially free of potassium ions in that the dry beverage 
mixture contains no potassium ions except that present in minor amounts of 
flavoring agents, preservatives, or other minor additives. 
The most preferred embodiment of the dry beverage mixture comprises 
0.5-50.0 meq. of calcium ions supplied by calcium ascorbate and a calcium 
compound selected from the group consisting of calcium aspartate, calcium 
orotate, and mixtures thereof, per 1.0-50.0 g. of the sweetener agent; and 
0.5-50.0 meq. of the magesium ions supplied by a magnesium compound 
selected from the group consisting of magnesium aspartate, magnesium 
orotate, and mixtures thereof, per 1.0-50.0 g. of the sweetener agent; and 
1.0-10.0 meq. of potassium ions supplied by a potassium compound selected 
from the group consisting of potassium aspartate, potassium orotate, 
potassium ascorbate, and mixtures thereof, per 1.0-50.0 g. of the 
sweetener agent. As was seen for the preferred and more preferred 
embodiment of the dry beverage mixture, the magnesium ions may be 
additionally supplied from magnesium ascorbate. The most preferred 
embodiment of the dry mixture compositions preferably additionally 
comprise per 1.0-50.0 g. of the sweetener agent; from about 0.3 g. to 
about 0.7 g. of the tartness agent; from about 0.3 g. to about 0.6 g. of 
the pH adjusting agent; from about 0.2 g. to about 0.6 g of the smoothness 
agent; and from about 0.1 ml. to about 36.0 ml. of the flavoring agent. 
Identical to the beverage compositions of the present invention, the 
preferred sweetener agent for the preferred, more preferred, and most 
preferred dry beverage compositions is selected from the group consisting 
of fructose, aspartame, steviocide, stevia, raubidiocide A and mixtures 
thereof; and the preferred tartness agent, smoothness, pH adjusting agent, 
and flavoring agent for the preferred, more preferred, and most preferred 
dry beverage compositions are respectively citric acid, potassium and/or 
calcium citrate, benzoic acid, and natural fruit juices. 
In yet another preferred embodiment of the present invention, the beverage 
composition of the present inventions are in a concentrate form for 
admixing with a liquid solvent to provide the beverage composition. A 
preferred embodiment of the beverage concentrate comprises the beverage 
solution containing per less than 354 ml.: 0.5-50.0 meq. of calcium ions 
supplied by calcium ascorbate and a calcium compound selected from the 
group consisting of calcium aspartate, calcium orotate, and mixtures 
thereof; and 1.0-50.0 g. of the sweetener agent. A more preferred 
embodiment of the beverage concentrate comprises the beverage solution 
containing per less than 354 ml.: 0.5-50.0 meq. of the calcium ions 
supplied by the respective calcium compounds; 0.5-50.0 meq. of magnesium 
ions supplied by a magnesium compound selected from the group consisting 
of magnesium aspartate, magnesium orotate, and mixtures thereof, and 
1.0-50.0 g. of the sweetener agent. The magnesium ions may be additionally 
supplied from magnesium ascorbate. The more preferred embodiment of the 
beverage concentrate is essentially free of potassium ions in that the 
beverage concentrate contains no potassium ions, except that present in 
minor amounts of flavoring agents, preservatives, or other minor 
additives. A more preferred embodiment of the beverage concentrate 
comprises the beverage solution containing per less than 354 ml.: 0.5-50.0 
meq. of the calcium ions supplied by the respective calcium compounds; 
0.5-50.0 meq. of magnesium ions supplied by the respective magnesium 
compounds; 1.0-10.0 meq. of potassium ions supplied by a potassium 
compound selected from the group consisting of potassium aspartate, 
potassium orotate, potassium ascorbate, and mixtures thereof; and 1.0-50.0 
g. of the sweetener agent. The preferred potassium compound in the 
beverage concentrate is the potassium chelate selected from the group 
consisting of potassium aspartate, potassium orotate, and mixtures 
thereof. 
The preferred, more preferred, and most preferred beverage concentrate of 
this invention, each additionally preferably comprises per less than 354 
ml. of the beverage solution: from 0.02 g. to 3.5 g of the tartness agent; 
from 0.10 g to 3.0 g. of the smoothness agent; from 0.25 g to 1.0 g. of 
the pH adjusting agent; and from 0.05 ml. to 50.0 ml. of the flavoring 
agent(s). 
The maximum concentration of each ingredient employed per each less than 
354 ml. of the beverage solution in the concentrate of this invention may 
be any reasonable maximum concentration that depends on the amount of 
volume of beverage solution less than 354 ml., readily discernible to 
those artisans possessing ordinary skill in the art. Not to be unduly 
limited hereby, suitable concentrations for each ingredient has been found 
to be a concentration five (5) times that of the consumable beverage 
solution, such that each 70.8 ml. of beverage solution contains: 0.5-50.0 
meq. of calcium ions supplied by the respective calcium compounds; 
0.5-50.0 meq. of magnesium ions supplied by the respective magnesium 
compounds; 1.0-10.0 meq. of potassium ions supplied by the respective 
potassium compounds; 1.0-50.0 g. of the sweetener agent; 0.02-3.5 g. of 
the tartness agent; 0.10-3.0 g. of the smoothness agent; 0.25-1.0 g. of 
the pH adjusting agent; 0.05-50.0 ml. of the flavoring agent(s). In this 
concentration, 283.2 ml of the liquid solvent has to be added to the 
concentrate to constitute a consumable beverage. Obviously, the higher the 
concentration of the ingredients in the concentrate of this invention, the 
more liquid solvent has to be added to formulate the beverage composition 
of this invention and make the concentrate palatable to one's taste buds. 
The amount of liquid solvent that has to be added to the concentrate to 
formulate the beverage composition of this invention is easily attainable 
from the known concentration of each of the ingredients in the 
concentrate. 
Another aspect of the present invention is the method of preparing or 
making the beverages of the present invention, including the beverage 
composition, the beverage dry mixture, and the beverage concentrate. In 
preparation of the preferred beverage compositions where the calcium 
chelate is employed, a predetermined volume of a liquid solvent (e.g. 
distilled water) is obtained which is the major component of the beverage 
solution and is the starting material in preparing and making the 
beverages. The exact quantity of liquid will depend and vary in accordance 
with the amount and solubility of beverage ingredients (e.g. fruit juices) 
and the nature of the liquid solvent (e.g. alcoholic vs. non-alcoholic) 
that are to be eventually added to the liquid solvent to produce the 
desired particular beverage composition, and the over-all volume of 
beverage or beverage solution that is to be produced. Generally, as was 
previously mentioned, from about 200 ml. to about 300 ml. of the liquid 
solvent should be used for every 354 ml. of beverage or beverage solution 
to be produced. The liquid solvent has to be heated to at least 70.degree. 
F. The maximum temperature being less than 230.degree. F. in order to 
curtail evaporation of the liquid solvent and as a matter of economics. 
Preferably, the liquid solvent is only heated from about 70.degree. F. to 
about 160.degree. F., with 180.degree. F. to 220.degree. F. being the more 
preferred temperature range from heating. 
After the liquid solvent has been heated to at least 70.degree. F., per 354 
ml. of the finished or finally prepared beverage product, 0.5-50.0 meq. of 
calcium ions are placed into the heated liquid solvent by adding calcium 
aspartate and/or calcium orotate to the heated liquid solvent. The heated 
liquid solvent mixture is stirred, preferably for at least one minute. 
More preferably, the heated liquid solvent mixture is stirred from about 
one minute to about five minutes, or until the calcium aspartate and/or 
calcium orotate is dissolved in the heated liquid solvent. In a more 
preferred embodiment of the invention, at least 15% of the 0.5-50 meq. of 
calcium ions are supplied by calcium ascorbate. Therefore, calcium 
ascorbate is preferably subsequently added to the stirred heated liquid 
solvent and the solution is stirred some more. The calcium ascorbate may 
be added to the heated liquid solvent along with the calcium aspartate 
and/or calcium orotate. 
I have discovered that calcium aspartate and/or calcium orotate is or are 
not readily soluble salt(s) and will not be dissolved into the liquid 
solvent unless it is heated to at least 70.degree. F., with 180.degree. F. 
to 220.degree. F. being the more preferred temperature. In producing the 
more preferred beverage composition and the most preferred beverage 
composition, the magnesium compound, or the magnesium compound and the 
potassium compound, may be added to the heated liquid solvent along with 
the calcium aspartate and/or calcium orotate (and the calcium ascorbate), 
or the respective compound or compounds may be added to the heated liquid 
solvent mixture after the calcium aspartate and/or calcium orotate (and 
the calcium ascorbate) has been dissolved therein. If the magnesium 
compound, or the magnesium compound and the potassium compound, is added 
to the heated liquid solvent mixture containing dissolved calcium 
aspartate and/or calcium orotate (and calcium ascorbate), the mixture 
should be stirred some more, say for at least one minute, to dissolve the 
compound(s) therein. All additions of the magnesium compound, or the 
magnesium and the potassium compound, should be such that each 354 ml. of 
the finished or finally prepared beverage product contains 0.5-50.0 meq. 
of magnesium ions or 0.5-50.0 meq. of magnesium ions and 1.0-10.0 meq. of 
potassium ions, respectively. 
The beverage compositions of this invention should be prepared to 
preferably contain the preservative benzoic acid, potassium or calcium 
benzoate, as a pH adjusting agent in order to adjust the pH of the 
beverage to from about 3.0 to about 4.5. These preservatives may be added 
to the heated liquid solvent before the calcium chelates have been added 
and dissolved therein by stirring; or the preservatives may be added to 
the heated liquid solvent mixture after the calcium chelates have been 
dissolved therein, or after the admixture and dissolution of the calcium 
chelate and the magnesium compound/potassium compound. In either case, the 
heated liquid solvent or the heated liquid solvent mixture, has to have a 
temperature of at least 70.degree. F., more preferably 180.degree. F., and 
after the addition of the benzoic acid, potassium or calcium benzoate, the 
resulting mixture has to be stirred vigorously for at least one minute. 
Preferably, the heated liquid solvent or the heated liquid solvent 
mixture, is heated to a temperature of between 180.degree. F. and 
230.degree. F. (more preferably between 185.degree. F. and 220.degree. F.) 
before the addition of the preservative, and after the preservative has 
been added, the resulting mixture is stirred vigorously from one minute to 
about five minutes. The addition of the perservative is to be at a 
quantity such that each 354 ml. of the finished or finally prepared 
beverage product contains from 0.25 g. to about 1.0 g. of the benzoic 
acid, potassium or calcium benzoate. 
After the preservative and the calcium chelate and the magnesium/potassium 
compound(s) have been dissolved into the heated liquid solvent, the 
tartness agent (i.e. citric acid) and the smoothness agent (potassium 
citrate and/or calcium cetrate) should be added to heated liquid solvent 
mixture and the resulting mixture stirred until the ingredients are 
dissolved. The addition of these two ingredients does not require the 
liquid solvent mixture to possess any particular elevated temperature. 
Preferably, though, the tartness agent and the smoothness agent are added 
to the liquid solvent mixture containing the preservative and the metallic 
ions (i.e. Ca, Mg and K ions) at the existing temperature of liquid 
solvent mixture after the mixture has been stirred to dissolve the 
preservative and the calcium chelate and the magnesium/potassium 
compound(s). This addition should be such that each 354 ml of the finished 
or finally prepared beverage product contains from about 0.02 g. to about 
3.5 g. of the tartness agent, and from about 0.10 g. to about 3.0 g. of 
the smoothness agent. 
The beverages of this invention include a sweetener agent(s) (i.e. frutose, 
aspartame, steviocide, stevia, or raubidiocide A) and preferably a 
flavoring agent (i.e. fruit juices). Before the sweetener agent is added, 
the liquid solvent mixture containing the preservative, and the calcium 
chelates and magnesium/potassium compound(s) has to be cooled down from 
the 180.degree.-200.degree. F. preferred temperature to a temperature of 
from about 100.degree. F. to about 160.degree. F., preferably from about 
140.degree. F. to about 160.degree. F. The sweetener agent is not added to 
the cooled down solution. The solution is now preferably further cooled to 
70.degree.-80.degree. F. before the addition of the flavoring agent in 
order not to possibly distort the taste or flavor of the flavoring agent. 
After the addition of these two particular ingredients to the solution, 
the resulting cooled mixture should be stirred until the two ingredients 
are throughly mixed. The finished or finally prepared beverage product 
contains from about 0.05 ml. to about 50.0 ml. of the flavoring agent(s) 
and from about 1.0 g. to about 50.0 g. of the sweetener agent(s), per 354 
ml. of final, consumable beverage solution. I have discovered that the 
calcium chelates of calcium aspartate and/or calcium orotate do not 
precipitate out of solution upon cooling, even down to the freezing point 
of the beverage. This differs and is unique with respect to other not 
readily soluble calcium salts which precipitate upon cooling, such as 
calcium carbonate and calcium gluconate. 
In the event that it is desired to prepare the dry beverage mixture 
embodiment of the present invention, the finally prepared beverage 
solution is dehydrated, in accordance with well known procedures, such as 
dehydrating under a vacuum means, etc., in order to remove all of the 
liquid solvent (such as by evaporation, sublimation, etc.) and any other 
evaporable liquids present, such as those in the natural fruit juices (the 
flavoring agent). 
The resulting dry beverage mixture is suitable for reconstituting with a 
suitable liquid solvent into the beverage solutions of this invention and 
the preferred dry beverage mixture comprises 0.5-50.0 meq. of calcium ions 
(supplied from the aspartate and/or the orotate, and the ascorbate of 
calcium) per 1.0-50.0 g. of the sweetener. The more preferred dry beverage 
mixture comprises 0.5-50.0 meq. of the calcium ions, per 1.0-50 g. of the 
sweetener; and 0.5-50.0 meq. of the magnesium ions (supplied from the 
aspartate and/or orotate, and, optionally, the ascorbate of magnesium) per 
1.0-50.0 g. of the sweetener. The most preferred dry beverage mixture 
comprises 0.5-50.0 meq. of the calcium ions, per 1.0-50 g. of the 
sweetener; 0.5-50.0 meq. of the magnesium ions, per 1.0-50.0 g. of the 
sweetener; and 1.0-10.0 meq. of potassium ions (supplied from the 
aspartate, orotate, or the ascorbate of the potassium) per 1.0-50.0 g. of 
the sweetener. More preferably, each of the dry beverage mixture of this 
invention, additionally comprises the dehydrated form of the additive 
ingredients (i.e. the tartness agent, the smoothness agent, the 
preservative and the flavoring agent). If a consumer wishes to prepare a 
beverage solution from the dry beverage mixture, the consumer simply 
measures out a predetermined volume of the liquid solvent that has been 
removed in dehydration and adds from approximately 11/2 tsps. to about 
21/2 tsps. of the preferred, more preferred, or most preferred dry 
beverage mixture for every 354 ml. of liquid solvent measured, which in a 
preferred embodiment of the invention is water. 
In the event that it is desired to prepare the concentrate form of the 
beverages, there are two alternative preferred procedures of performing 
such preparation. One preferred procedure would be to start with less than 
the required volume of the liquid solvent that is used in the preparation 
of the finally prepared beverage immediately available for consumption. 
Another preferred procedure would be to partially dehydrate the finally 
prepared beverage to remove only a portion of the liquid solvent and any 
other evaporable liquids present emanating from the other additives, 
especially the natural fruit juices. The finally prepared preferred 
beverage concentrate comprises a beverage solution containing per less 
than 354 ml.: 0.5-50.0 meq. of the calcium ions from the respective 
calcium compounds, and 1.0-50 g. of the sweetener agent. The more 
preferred beverage concentrate when finally prepared comprises a beverage 
solution containing per less than 354 ml.: 0.5-50 meq. of the calcium ions 
from the respective calcium compounds; 0.5-50 meq. of the magnesium ions 
from the respective magnesium compounds; and 1.0-50 g. of the sweetener 
agent. The most preferred beverage concentrate when finally prepared 
comprises a beverage solution containing per less than 354 ml: 0.5-50.0 
meq. of calcium ions from the respective calcium compounds; 0.5-50.0 meq. 
of magnesium ions from the respective magnesium compounds; 1.0-10.0 meq. 
of the potassium ions from the respective potassium compounds; and 1.0- 
50.0 g. of the sweetener agent. More preferably, each of the beverage 
concentrates of this invention additionally comprises the dehydrated form 
or the concentrated form of the additive ingredients (i.e. the flavoring 
agent, etc.). If a consumer wishes to prepare a beverage solution from the 
beverage concentrate, the consumer would add a predetermined volume of the 
liquid solvent (preferably carbonated water or beer) to predetermined 
volume of the beverage concentrate to reconstitute the consumable beverage 
solution or the beverage. The amount of liquid solvent to be added would 
obviously depend on the amount and type of liquid solvent missing from the 
beverage concentrate that would constitute the consumable beverage. 
It is to be understood that while the stated particular tartness agent, 
smoothness agent(s), pH regulating agent, and flavoring agent(s) are the 
preferred for the purposes of this invention, it is not intended that any 
particular agent(s) that has been selected as the preferred, is to be 
construed to unduly limit the scope of my invention. Other particular 
tartness agent(s), smoothness agent(s), pH regulating agent(s), and 
flavoring agent(s) may be within the scope of my invention. 
My invention will be illustrated by the following set forth examples which 
are given by way of illustration and not by any limitations. All 
parameters such as concentrations, mixing proportions, temperatures, 
pressures, rates, compounds, etc. submitted in these examples are not to 
be construed to unduly limit the scope of my invention. It is recognized 
that some test applicable to human beings yield results which at best are 
merely qualitative results due to the subjective sensations of the human 
subjects. It is further recognized that subjective sensations may vary so 
substantially from individual to individual that it is difficult to 
delineate well defined, quantitative results. However, even though test 
results are evidence of subjective sensations, it is believed that they 
are of objective value if unanimously elicited from a large number (e.g. 
100 or more) of different human subjects.

EXAMPLE I 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml.: 
(1) 20 meq. of calcium from aspartate salt 
(2) 32 meq. of magnesium from aspartate salt 
(3) 4 meq. of potassium from aspartate salt 
(4) 0.42 g. of citric acid 
(5) 0.31 g. of potassium citrate 
(6) 0.38 g. of benzoic acid 
(7) 3.86 g. of fructose or 1.93 g. steviocide or Raubidiocide A 
(8) 35.4 ml. of natural citrus or other juice 
(9) Balance carbonated water 
One-hundred (100) human subjects with a known average high blood pressure 
of 140/90 are administered the beverage in 354 ml. quantities twice daily. 
After three (3) months the average blood pressure for the human subjects 
is 125/80, proving that on an average the beverage lowers mean blood 
pressure. 
EXAMPLE II 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml.: 
(1) 20 meq. of calcium aspartate 
(2) 4 meq. of potassium aspartate 
(3) 0.42 g. of citric acid 
(4) 0.31 g. of potassium citrate 
(5) 0.38 g. of benzoic acid 
(6) 3.86 g. of fructose or 1.93 g. steviocide or Raubidiocide A 
(7) 35.4 ml of natural citrus or other juice 
(8) Balance carbonated water 
One-hundred (100) human subjects with known average high blood pressure of 
140/90 are administered the beverage in 354 ml. quantities twice daily. 
After three (3) months the average blood pressure for the human subjects 
is 136/86, proving that on an average the beverage lowers blood pressure. 
This embodiment of the beverage does not lower mean blood pressure as much 
as the embodiment of Example I due to the absence of Mg ion. 
EXAMPLE III 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml.: 
(1) 20 meq. 0f Calcium from Ascorbate, and Aspartate and/or Orotate salt 
(2) 32 meq 0f Magnesium from Ascorbate, and Aspartate and/or Orotate Salt 
(3) 28.32 g. of Hop-Malt Extract (any malt or hop based extract) 
(4) Balance carbonated water 
One hundred (100) human subjects with a known average high blood pressure 
of 140/90 are administered the beverage in 354 ml. quantities twice daily. 
After three (3) months, the average blood pressure for the human subjects 
is 127/85, proving that on an average the beverage lowers blood mean 
pressure. 
EXAMPLE IV 
A beverage is prepared from one gallon of water, to which is added 40 meq. 
of potassium chloride, 8 meq. of calcium gluconate, 2 meq. of magnesium 
chloride and 8 ounces of sucrose. Flavoring is added to the homogeneous 
mixture, along with a trace of stabilizer. 
One-hundred (100) human subjects with a known average high blood pressure 
of 140/90 are administered the beverage in 354 ml. quantities twice daily. 
After (3) months the average blood pressure for the human subjects is 
142/92, with a number of the human subjects having nausea, stomach cramps, 
muscle spasm and reverse osmolarity from the beverage. 
EXAMPLE V 
A beverage is attempted to be prepared from one gallon of water, to which 
is added 40 meq. of potassium aspartate, 8 meq. of calcium aspartate, 2 
meq. of magnesium aspartate and 8 ounces of sucrose. It is found that the 
mixture is not homogeneous because calcium aspartate is not readily 
soluble in water. If calcium orotate is substituted for the calcium 
aspartate, similar results would be observed. The aspartate and orotate 
salts of calcium are not readily soluble in water. 
EXAMPLE VI 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml.: 
(1) 30 meq. of potassium aspartate 
(2) 10 meq. of calcium aspartate 
(3) 3 meq. of magnesium aspartate 
(4) 3.86 g. of fructose 
(5) Balance water 
One hundred-twenty (120) human subjects with a known calcium deficiency 
(hypercalcemia) are administered the beverage in 354 ml. quantities twice 
daily. After three (3) months, the calcium deficiency still remain in all 
human subjects, with a number of the human subjects having nausea and 
hyperkalemia from an over-medication with potassium ions and a limitation 
of fluid intake into the body. 
EXAMPLE VII 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml.: 
(1) 1.0 meq. of calcium from calcium orotate 
(2) 1.0 meq. of magnesium from magnesium orotate 
(3) 1.0 meq. of potassium from potassium orotate 
(4) 0.42 g. of citric acid 
(5) 0.31 g. of benzoic acid 
(6) 3.86g. of fructose or 1.93 g. steviocide or Raubidiocide A 
(7) 0.36 g. of calcium citrate 
(8) 35.4 ml. of natural citrus or other fruit juice 
(9) Balance carbonated water 
One hundred-twenty (120) human subjects with a known calcium deficiency are 
administered the beverage in 354 ml. quantities twice daily. After three 
(3) months a number of the human subjects have a decrease or no calcium 
deficiency, with no human subjects having nausea, hyperkalemia, gastric 
upset or stomach bloating. 
EXAMPLE VIII 
Repeat Example VII but with the beverage solution containing per 354 ml.: 
(1) 50.0 meq. of calcium from calcium orotate 
(2) 50.0 meq. of magnesium from magnesium orotate 
(3) 10.0 meq. of potassium from potassium orotate 
(4) 0.42 g. of citric acid 
(5) 0.38 g. of benzoic acid 
(6) 3.86 g. of fructose, or 1.93 g. steviocide or Raubidiocide A 
(7) 0.36 g. of calcium citrate 
(8) 35.4 ml. of natural citrus or fruit juice 
(9) Balance carbonated water 
The test results show that over 90% of the human subjects have no calcium 
deficiency, with no human subjects having nausea, hyperkalemina, gastric 
upset or stomach bloating. The results also show that over 90% of the 
human subjects have a lowering of their average blood pressure from their 
average blood pressure taken before the test. 
EXAMPLE IX 
Take the beverage of Example I and administer it in 354 ml. quantities 
twice daily to one-hundred twenty (120) human female subjects who have a 
history of hypertension and premenstrual syndrome. After three (3) months 
the hypertension has been reduced and the symptons of premenstrual 
syndrome are milder in the majority of the female subjects. 
EXAMPLE X 
Take the beverage of Example III and administer it in 354 ml. quantities 
twice daily to one-hundred twenty (120) male and female subjects who have 
a history of hypertension. After three (3) months, the mean blood pressure 
of the subjects show no net increase as might be expected from other malt 
beverages. 
EXAMPLE XI 
Repeat Example IX with the beverage of Example VII and find the same 
results. 
EXAMPLE XII 
Repeat Example IX with the beverage of Example VIII and find the same 
results. 
EXAMPLE XIII 
Repeat Example IX with the beverage of Example IV and find that the 
hypertension and symptoms of premenstrual syndrome of the female human 
subjects are not decreased. As a matter of fact, the majority of the 
female human subjects would also experience nausea, stomach cramps and 
muscle cramps which would aggravate the hypertension and premenstrual 
syndrome. 
EXAMPLE XIV 
Repeat example IX with the beverage of Example VI and find the results of 
Example XIII. 
EXAMPLE XV 
Tablets containing 250 mg. of potassium aspartate (about 1.5 meq.), 250 mg. 
of magnesium aspartate (about 3.2 meq.), and 5 mg of the A.T.P. (adenosine 
triphosphate) are administered twice daily to human subjects with a known 
average blood pressure of 140/90 and with calcium deficiency. After three 
(3) months the average blood pressure is not lowered and there is no 
decrease in calcium deficiency. 
EXAMPLE XVI 
Repeat Example XV for tablets containing 0.30 mg of only magnesium 
aspartate (about 0.004 meq.) but administer 5 tablets per 24 hours and 
find similar results. 
EXAMPLE XVII 
Repeat Example XV for tablets only containing 0.30 mg potassium aspartate 
(about 0.002 meq.) and find similar results. 
EXAMPLE XVIII 
Repeat Example XV for tablets only containing 250 mg potassium aspartate 
(about 1.5 meq.) and 6 mg A.T.P., but administer 1-6 times daily and find 
similar results. 
EXAMPLE XIX 
Repeat Example XV with 5 cc of a 2.5% solution of potassium aspartate 
(about 0.7 meq. of potassium aspartate) and find similar results. 
EXAMPLE XX 
Repeat Example XV with 5 cc of a 2.5% solution of magnesium aspartate 
(about 1.6 meq. of magnesium aspartate) and find similar results. 
EXAMPLE XXI 
Take the beverage of Example I and administer it twice daily one-hundred 
(100) human subjects having condition of anoxia. After three (3) months 
the cardiac tolerance to the anoxia condition generally increased (in some 
cases doubled) in a number of human subjects. 
EXAMPLE XXII 
Repeat Example XXI with the beverage of Example IV and find generally no 
increase in cardiac tolerance for a majority of the human subjects. 
EXAMPLE XXIII 
Repeat Example XXI with the beverage of Example VI and find the similar 
results of Example XXII. 
EXAMPLE XXIV 
A liquid solvent is obtained, preferably a potable water that has been 
demineralized, carbon filtered. Heat the liquid solvent to 100 F. For each 
150 ml. of the heated liquid solvent add 0.5-50.0 meq. of calcium ions 
supplied by calcium ascorbate and a calcium compound selected from calcium 
aspartate, calcium orotate, and mixture thereof. Stir the heated solvent 
mixture until the calcium chelates are dissolved (approximately 1-5 
minutes). Maintain the heated solvent mixture at 100 F., and add about 
0.15 g. of the benzoic acid per 150 ml. of the heated liquid solvent. Stir 
the resulting mixture (e.g. 1-5 mins.) until the benzoic acid is 
dissolved. Per each 150 ml of about resulting mixture about 0.18 g. of 
citric acid and 0.12 g. of calcium citrate is added. The mixture is 
stirred again to homogenize the citric acid and calcium citrate into the 
mixture. The mixture is then cooled down to about 70 F. per 150 ml. of 
mixture, 10.2 g. of fructose is added, and stirred into dissolution; and 
subsequently, while the solution is still cool at about 70 F., 
approximately 15 ml. of natural fruit juice/150 ml. of cool solution is 
added as a flavoring agent and the solution is stirred. Make-up liquid 
solvent is now added until a cool beverage solution is produced containing 
per 354 ml.: 0.5-50.0 meq. of calcium ions supplied by calcium ascorbate 
and calcium aspartate and/or calcium orotate, 0.38 g. of benzoic acid, 
0.42 g. of citric acid, 0.31 g. of calcium citrate and 40 ml. of natural 
fruit juice as the flavoring agent. Carbon dioxide is now added to 3.75 
volumes. 
EXAMPLE XXV 
Repeat Example XXIV but the liquid solvent is at a temperature of 60 F. 
When the calcium aspartate and/or calcium orotate is added, it is 
discovered that it will not dissolve into the liquid solvent, even with 
stirring. The beverage can not be produced. If the temperature of the 
liquid solvent is raised to about 70 F., it is discovered that the calcium 
aspartate and/or calcium orotate begins to dissolve in solution and the 
beverage can be produced. 
EXAMPLE XXVI 
Repeat Example XXIV but allow the temperature of the heated liquid solvent 
containing the dissolved calcium chelates to decrease to about 60 F. When 
the benzoic acid is added, it is discovered that it will not dissolve in 
the liquid mixture even with vigorous stirring. The preservative for the 
beverage can not be dissolved into solution. If the temperature of the 
liquid mixture is raised to about 70.degree. F., it is discovered that the 
benzoic acid presevative begins to dissolve in the calcium chelates 
solution with vigorous stirring. If the temperature of the subsequent 
liquid mixture is cooled down to 50.degree. F., it is discovered that the 
calcium chelates of calcium aspartate and/or calcium orotate have not 
precipitated out of solution. 
EXAMPLE XXVII 
Distilled water is obtained and is heated to 120.degree. F. For each 200 
ml. of the heated distilled water, 0.38 g. of benzoic acid is added to the 
heated water, and the heated water containing the benzoic acid is stirred 
or shaken vigorously (typically 1-5 minutes) in order to dissolve the 
benzoic acid. After the benzoic acid has been dissolved into the heated 
water, and while the temperature of the benzoic acid solutions is at least 
70.degree. F., preferably 120.degree. F., 0.5-50.0 meq. of calcium ions 
from calcium aspartate, per each 200 ml. of benzoic acid solution, is 
added to the benzoic acid solution, and the resulting mixture is stirred 
for at least 1 minute to dissolve the calcium aspartate which is not 
readily dissolvable in water. In the more preferred embodiment of the 
invention, 0.5-50.0 meq. of magnesium ions from magnesium aspartate, per 
each 200 ml. of the mixture (which does not have to be any particular 
heated temperature at this stage, is added to the mixture containing 
dissolved benzoic acid and calcium aspartate. The solution is stirred for 
at least one minute to dissolve the magnesium aspartate into solution. The 
most preferred embodiment of the invention calls for 1.0-10.0 meq. of 
potassium ions from potassium aspartate to be added, per 200 ml. of the 
mixture containing the calcium and magnesium ion, which is not required to 
be at any particular heated temperature for the potassium aspartate to be 
dissolved therein. After the potassium aspartate has been added, the 
mixture is subsequently stirred to homogenize the aspartates. For each 200 
ml. of mixture containing the calcium, magnesium and potassium ions the 
following additives may be added: 0.42 g. of citric acid and 0.31 g. of 
potassium citrate. The mixture is then stirred until the additives are in 
solution, and then the mixture is cooled down to about 45.degree. F. Per 
200 ml. of mixtures, 24 g. of fructose is added and stirred into solution; 
and subsequently, while the solution is still cool at about 45.degree. F., 
approximately 40 ml. of natural fruit juice per 200 ml. of cool solution 
is added as a flavoring agent followed by stirring. The calcium aspartate 
does not precipitate out of solution. The beverage solution may be 
packaged/canned in this form and sold as a concentrate. Make-up carbonated 
water may be added until the beverage solution contains all of the meq. of 
the compounds and the respective grams and ml. of the additives per 354 
ml. of beverage solution. 
EXAMPLE XXVIII 
A liquid solvent is obtained, preferably a potable water that has been 
demineralized, carbon filtered. Heat the liquid solvent to 180.degree. F.. 
For each 354 ml. of the heated liquid solvent add 0.5-50.0 meq. of a 
calcium chelate selected from calcium aspartate, calcium orotate, and 
mixtures thereof. Stir the heated solvent mixture until the calcium 
chelate is dissolved, (approximately 1-5 minutes). Maintain the heated 
solvent mixture at 180.degree. F., and add 0.31 g. of benzoic acid per 354 
ml. of the heated liquid solvent. Stir the resulting mixture (e.g. 1-5 
mins.) until the benzoic acid is dissolved. Per each 354 ml. of resulting 
mixture, next add 0.42 g. of citric acid and 0.36 g. of potassium citrate. 
The mixture is stirred again to homogenize the citric acid and calcium 
citrate into the mixture. The mixture is then cooled to 70.degree. F. and 
10.2 g. of fructose or 1.93 g. of steviocide or Raubidicide A is added and 
stirred into dissolution. 
While the solution is still cool at about 70.degree. F., 5 g. of calcium 
ascorbate and 35.4 ml. of natural fruit juice is added per each 354 ml. 
and the solution is further stirred. 
Make-up liquid solvent is now added until an all cool beverage solution is 
produced containing per 354 ml.: 0.5-50.0 meq. of the calcium chelate, 
0.31 g. of benzoic acid, 42 g. of citric acid, 0.36 g. potassium citrate, 
10.2 g. fructose or 1.93 g. of steviocide or Raubidicide A, 5 g. calcium 
ascorbate and 35.4 ml. natural fruit juice. Carbon dioxide is next added 
to 3.75 volumes. 
EXAMPLE XXIX 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml. 20 meq. of calcium 
from aspartate salt or orotate salt. 
The calcium is tagged with radioactive strontium 65. Prepare a beverage 
having per 354 ml. 20 meq. of calcium from the gluconate salt. The calcium 
in the calcium gluconate is tagged with radioactive strontium 65. 
Administer a predetermined quantity of the calcium aspartate or calcium 
orotate beverage to a set of 50 rats for ingestion and administer the same 
predetermined quantity of the calcium gluconate beverage to another set of 
50 rats for ingestion. 
Measure by RIA the amount of the calcium in the blood stream of each set of 
50 rats by taking blood samples at one hour intervals. After (6) hours and 
at each hour interval find a greater quantity or concentration of calcium 
in the blood stream of the set of rats that ingested the calcium aspartate 
or calcium orotate, proving that the aspartate and orotate salts of 
calcium supply a rapidly and higher absorbable source of calcium than 
calcium gluconate. 
EXAMPLE XXX 
Repeat Example XXIX with 1 meq. of calcium aspartate or orotate and 1 meq. 
of calcium gluconate and find similar results. 
EXAMPLE XXXI 
Repeat Example XXIX with 50 meq. of calcium aspartate or orotate and 50 
meq. of calcium gluconate and find similar results. 
EXAMPLE XXXII 
Repeat Example XXIX for each of calcium acetate, chloride, iodide, lactate, 
maleate, nitrate and proprionate, and find with respect to each calcium 
compound that the aspartate and orotate salts of calcium supply a rapidly 
and higher absorbable source of calcium than each of the calcium compound. 
EXAMPLE XXXIII 
Repeat Example XXIX for other calcium chelates (e.g. calcium lactate, 
calcium with lycine, calcium glutamate, etc.) other than calcium aspartate 
and/or orotate and find that the aspartate and orotate salts of calcium 
supply a more rapid and higher absorbable source of calcium than the other 
calcium chelates. 
EXAMPLE XXXIV 
A beverage is prepared in accordance with the previous mentioned procedure 
such that the beverage solution contains per 354 ml.: 
(1) 20 meq. of calcium from the ascorbate salt and the aspartate salt 
(2) 32 meq. of magnesium from the ascorbate salt and the aspartate salt 
(3) 0.42 g. of citric acid 
(4) 0.31 g. of potassium citrate 
(5) 0.38 g. of benzoic acid 
(6) 1.93 g. of steviocide or Raubidiocide A 
(7) 35.4 ml. of natural citrus juice or flavoring agent 
(8) Balance carbonated water 
One-hundred (100) human subjects are administered 354 ml. of the beverage. 
After a period of time sufficient for the beverage to get into the blood 
stream (30 min. to 1 hour) each of the human subjects consume four (4) 
martinis with the same quantity of alcohol. Blood samples are taken every 
hour on the hour for six (6) hours from the human subjects after the 
martini consumption and the amount/concentration of alcohol, and 
amount/concentration of aldehydes, in the blood of each human subject is 
recorded. 
Three (3) days later and with the same 100 human subjects, the experiment 
is repeated but with the beverage of Example IV. Three (3) days later the 
experiment is again repeated with no beverage being administered and the 
blood samples are taken every hour on the hour to determine the 
amount/concentration of blood alcohol, and the amount/concentration of 
aldehydes in the blood with no beverage. The results show that the 
beverage of Example IV does not lower the amount/concentration of blood 
alcohol and the amount/concentration of aldehydes in the blood; and that 
the beverage of this invention lowers the amount/concentration of blood 
alcohol and the amount/concentration of aldehydes in the blood of a human 
body by 10 to 40%, with 30% being the mean. This proves that the beverage 
compositions accelerates the reduction of blood alcohol and aldehydes to 
inactive forms. 
EXAMPLE XXXV 
Repeat Example XXXIV but with the beverage of Examples VII and VIII and 
find similar results in that the amount/concentration blood alcohol and 
the amount/concentration of aldehydes in the blood are lowered from 10 to 
40%. 
EXAMPLE XXXVI 
Repeat Example XXXIV but with the Tablets of Examples XV, XVI, XVII and 
XVIII and find that the tablets do not lower the amount/concentration 
blood alcohol nor the amount/concentration of aldehydes in the blood, but 
the beverage of this invention does. 
EXAMPLE XXXVII 
Repeat Example XXXIV but with the beverage additionally including per 354 
ml. 5 g. of calcium ascorbate and 1-20 mg. of Vitamin B.sub.6 and find 
that the amount/concentration of blood alcohol and the 
amount/concentration of aldehydes in the blood are lowered by an 
additional 5%. The ascorbate in combination with Vitamin B.sub.6 
interferes with the conversion of alcohol in the blood stream into 
inactive forms, and enables the reduced form to be passed in urine. 
EXAMPLE XXXVIII 
Repeat Example XXIX but destroy each set of rats after six (6) hours and 
analyze the tissues of each set of rats and find that a greater quantity 
or concentration of calcium in the tissues of the set of rats that 
ingested the calcium aspartate or calcium orotate. 
EXAMPLE XXXIX 
Repeat the procedure of Example XXIX with a beverage containing 20 meq. of 
calcium ion from aspartate salt or orotate salt and 20 meq. of magnesium 
ion from aspartate salt or orotate salt. When the amount of the calcium in 
the blood stream of each set of rats are measured, it is found that a 
greater quantity of the calcium ion has been transported or absorbed into 
the blood stream than if the 20 meq. of the calcium ion from asspartate 
salt or orotate salt was employed alone. 
EXAMPLE XXXX 
Repeat the procedure of Examples XXIX for 50 meq. of calcium ion from 
aspartate salt, and Example XXXIX for 50 meq. of calcium ion and 0.5-50 
meq. of magnesium ion, both from aspartate salt, and find similar results 
in that a greater quantity of the calcium ion is absorbed into the blood 
stream than if 50 meq. of calcium ion is employed alone. 
EXAMPLE XXXXI 
Repeat Example XXXX but for 1 meq. of calcium ion and find similar results. 
EXAMPLE XXXXII 
Repeat the procedure of Example XXIX but for 20 meq. of magnesium ions from 
aspartate salt. Tag the magnesium radioactively. Measure the quantity of 
magnesium in the blood of each set of rats hourly for six (6) hours. Three 
(3) days later repeat the procedure of Example XXIX but for 20 meq. of 
calcium ions from aspartate salt. Measure the quantity of calcium in the 
blood of each set of rats hourly for six (6) hours. Six (6) days later 
repeat the procedure of Example XXIX but for 20 meq. of calcium ions and 
20 meq. of magnesium ions together and find synergistic results in that a 
greater quantity of the calcium ions and/or magnesium ions (i.e. either 
singly or in combination) are absorbed into the blood stream with the use 
of 20 meq. of calcium ions plus 20 meq. of magnesium ions, than if 20 meq. 
of calcium ion is employed alone, or if 20 meq. of magnesium ions is 
employed alone. The magnesium ions in combination with the calcium ions 
accelerates the absorption of the calcium ion (and the magnesium ions) 
into the blood stream. 
EXAMPLE XXXXIII 
Repeat Examples XXXIX, XXXX, XXXXI, XXXXII and destroy each set of rats 
after six (6) hours and analyze the tissues of each set of rats and find 
similar synergistic results. The magnesium ions in combination with the 
calcium ions accelerates the absorption of the calcium ions (and the 
magnesium ions) into the tissues. 
EXAMPLE XXXXIV 
Repeat the procedure of Example XXIX for Examples XXXIX-XXXXIII for 1-10 
meq. of potassium ions from aspartate or orotate salt (singly, in 
combination with the magnesium ions, and in combination with calcium ions 
and magnesium ions) and find similar synergistic results in all cases. The 
magnesium ions in combination with the calcium ions and potassium ions 
accelerates the absorption of the calcium ions, the calcium ions and the 
potassium ions (and the magnesium ions) into the blood stream, and into 
the tissues. 
EXAMPLE XXXXV 
Repeat the procedure of Example XXIX with a beverage containing per 354 ml. 
20 meq. of calcium ascorbate; and for a beverage containing per 354 ml. 20 
meq. of calcium ions supplied by calcium ascorbate and calcium aspartate 
and/or calcium orotate, and wherein 1.2 to 2.8 parts of calcium aspartate 
and/or calcium orotate are employed per each part calcium ascorbate. When 
the amount/concentration of calcium in the blood stream of each set of 
rats are measured, it is found that a greater quantity of the 20 meq. of 
calcium ions has been transported or absorbed into the blood stream than 
if 20 meq. of calcium ascorbate is employed alone or if calcium aspartate 
and/or orotate is employed alone. This proves combining calcium ascorbate 
with calcium aspartate and/or calcium orotate has a synergistic effect 
with respect to the amount/concentration of calcium ions that are absorbed 
into the blood. 
EXAMPLE XXXXVI 
Repeat Example XXXXV for other meqs. of calcium ions from 0.5 to 50 meqs. 
and find similar results. Calcium ascorbate unexpectedly aids and has a 
synergistic effect upon the absorption and transportation of calcium ions 
into the blood stream when employed with calcium aspartate and/or calcium 
orotate. 
EXAMPLE XXXXVII 
Repeat Example XXXXII, and three days after the last ingestion (or a time 
sufficient for the blood stream of the rats to be cleared of calcium 
and/or magnesium ions) repeat the procedure of Example XXIX for per 354 
ml. of beverage solution 20 meq. of magnesium ions from aspartate salt 
plus 20 meq. of calcium ions supplied by calcium ascorbate and calcium 
aspartate and/or orotate, wherein 1.2 to 2.8 parts of calcium aspartate 
and/or calcium orotate are employed per each part calcium ascorbate, and 
find further and greater synergistic results in that a greater quantity of 
the calcium ions and/or magnesium ions are absorbed into the blood stream 
with the use of 20 meq. of calcium ion supplied by calcium ascorbate and 
calcium aspartate and/or orotate plus 20 meqs. of megnesium ions, than 
with the use of 20 meq. of calcium ions from aspartate salt plus 20 meq. 
of megnesium ions from aspartate salt. Calcium ascorbate catalyses the 
transportation or absorption of the calcium ions (and the magnesium ions) 
into the blood stream. 
EXAMPLE XXXXVIII 
Repeat Example XXXXVII for other meqs. of calcium ions and magnesium ions 
from 0.5 to 50 meqs. and find similar results. The ascorbate anion 
unexpectedly has a synergistic effect upon the absorption and 
transportation of calcium ions (and magnesium ions) into the blood stream 
when employed with calcium aspartate and/or calcium orotate and magnesium 
ions supplied by magnesium aspartate and/or magnesium orotate. 
EXAMPLE XXXXIX 
A first beverage is prepared in accordance with the previous mentioned 
procedure such that the first beverage solution contains per 354 ml. 10 
meq. of calcium ions from calcium aspartate and/or calcium orotate. 
Administer a first predetermined quantity of the first beverage daily for 
one (1) year to a first set of 50 one (1) year old rats for ingestion. 
This first set of one (1) year old rats are in an ascorbic acid free diet 
(i.e. Vitamin C) and an ascorbate salt free diet (especially of the 
cations K, Mg and Ca). 
A second beverage is prepared in accordance with the previous mentioned 
procedure such that the second beverage solution contains per 354 ml. 10 
meq. of calcium ions from calcium ascorbate and calcium aspartate and/or 
calcium orotate wherein 1.2 to 2.8 parts of calcium aspartate and/or 
calcium orotate are employed per each calcium ascorbate. Alternatively, at 
least 15% of the calcium ions are supplied by the calcium ascorbate. 
Administer a second predetermined quantity (which is identical to the 
first predetermined quantity) of the second beverage daily for one (1) 
year to a second set of 50 one (1) year old rats for ingestion. The 
remainder of the diet fro the second set of rats is identical to the 
remainder of the diet for the first set of rats. After one (1) year 
destroy both sets of rats, measure the bone mass of both sets of rats, and 
find that on an average the bone mass of the second set of rats are from 
20 wt. % to about 30 wt. % greater than the bone mass of the first set of 
rats. 
EXAMPLE XXXXX 
Repeat Example XXXXIX for other meqs. of calcium ions ranging from 0.5 to 
50 meq. and find similar results, proving that the ascorbate anion of 
calcium ascorbate aids the use by the human body of the calcium ions that 
have been absorbed into the blood for formation of bone matrix by 
directing, causing and/or facilitating the cause of the calcium ions to 
migrate or travel, or the like, to the bones of the human body to form the 
bone matrix. 
EXAMPLE XXXXXI 
Repeat Examples XXXXIX and XXXXX but with the first and second beverage 
solutions also containing 0.5-5.0 meq. of magnesium ions supplied by 
magnesium aspartate and/or magnesium orotate find an even greater 
synergistic results in that on an average the bone mass of the second set 
of rats are from 25 wt. % to about 35 wt. % greater than the bone mass of 
the first set of rats. Thus, an even greater bone mass can be formed by 
employment of the ascorbate anion in combination with the magnesium ions 
supplied by the magnesium aspartate and/or magnesium orotate. The 
magnesium ions in combination with the ascorbate anion catalyses or 
accelerates the directing or channeling of the calcium ions towards the 
bones for use in the formation bone matrix. 
While the present invention has been described herein with reference to 
particular embodiments thereof, a latitude of modification, various 
changes and substitutions are intended in the foregoing disclosures, and 
it will be appreciated that in some instances some features of the 
invention will be employed without a corresponding use of other features 
without departing from the scope of the invention as set forth.